Renin-angiotensin system blockers and susceptibility to COVID-19: a multinational open science cohort study

Following over 1.1 million antihypertensive users between Nov 2019 and Jan 2020, there was no significant difference in relative COVID-19 diagnosis risk comparing ACE inhibitors or ARBs vs calcium channel blocker or thiazide diuretic, nor any difference for mono/combination use.